RV3391A

Pierre Fabre Dermo Cosmetique · Phase 3 active Small molecule

RV3391A is a topical agent developed for dermatological use, likely targeting inflammatory or proliferative skin conditions.

RV3391A is a topical agent developed for dermatological use, likely targeting inflammatory or proliferative skin conditions. Used for Dermatological indication (specific indication not publicly disclosed).

At a glance

Generic name	RV3391A
Sponsor	Pierre Fabre Dermo Cosmetique
Modality	Small molecule
Therapeutic area	Dermatology
Phase	Phase 3

Mechanism of action

As a Pierre Fabre Dermo Cosmetique product in phase 3 development, RV3391A is designed for cutaneous application. Without disclosed mechanism details, the compound appears to be investigated for a skin-related indication, potentially involving modulation of inflammatory pathways or keratinocyte function common to dermatological therapeutics.

Approved indications

Dermatological indication (specific indication not publicly disclosed)

Common side effects

No common side effects on file.

Key clinical trials

Physiopathological Study and Pharmacological Modulation of Cutaneous Atrophy's Markers Induced by Glucocorticoids (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

RV3391A CI brief — competitive landscape report
RV3391A updates RSS · CI watch RSS
Pierre Fabre Dermo Cosmetique portfolio CI